Horizon’s teprotumumab hits major R&D milestone
Horizon Pharma has announced positive Phase III clinical trial data for teprotumumab, as a treatment for active thyroid eye disease (TED).
Read More
Tag: active thyroid eye disease
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
